Description
The global bio-imaging market was valued at $2.2bn in 2015 and is forecast to grow at a modest 16.4% CAGR between 2015 and 2024, culminating in 2024 global sales of $8.6bn.
Bio-imaging is the most advanced form of the non-invasively visualized biological process of living objects or systems. It doesn’t interfere with life process, however, helps to obtain the 3-D structure of observed specimen from the outside. It helps in observation of subcellular structure to the entire cell to tissue and entire multicellular organism. There could be various sources for imaging as (light, fluorescence, electrons, ultrasound, X-ray, magnetic resonance and positrons).
Bio-imaging has seen development in recent time with the inclusion of super-resolution, two-photon fluorescence excitation microscopy, fluorescence recovery/redistribution after photobleaching (FRAP). Image processing methods, such as denoising, segmentation, de-convolution and registration methods has added significance to the overall process.
Need for accurate diagnosis, physician’s lack of time and increasing number of bio-imaging diagnostic centers will be driving force behind bio-imaging technology. With the advancement of bioinformatics and healthcare IT, usage of bio-imaging is going to increase.
Increasing aging population, lifestyle diseases, rising cases of cancer disease, there is a growing demand for continuous diagnostics and early stage diagnosis. Improved R&D in molecular imaging technologies are anticipated to drive the bio-imaging market. With recent development such as pill camera, system design improvement and network within hospital and doctors located in different parts of the world are going to increase the demand for the bio-imaging industry.
Image processing methods, such as denoising, segmentation, deconvolution and registration methods, feature recognition and classification will further boost the bio-imaging and related data analysis and statistical tools.
Recent developments in bio-imaging include super-resolution, two-photon fluorescence excitation microscopy, fluorescence recovery/redistribution after photobleaching (FRAP), and fluorescence resonance energy transfer (FRET). Within the last few years, a strong interaction between Molecular Biology and Bioimaging has led to the design of an increasing number of Nanosensors for many ions and metabolites. When expressed or incorporated in cells, these cells become self-reporting for the metabolite in question.
“Optimal Price Point (OPP) for Bio-imaging Products”
Estimated Average product cost – $ xx globally. However, with improving access and availability of options; OPP and range of acceptable Prices (RAP) are going to change. We at Ameri Research continuously track these prices with our proprietary pricing model.
Bioimaging is an upcoming new technology which represents a significant proportion of bioscience research. Some of leading development centers as Durham Centre for Bioimaging Technology bringing cutting age technology such as instrumentation, chemical probes and visualization, demonstrating the strength of applying these to real biological challenges. This will be revolutionary in plant imaging and identifying cause of many diseases will ultimately address the challenge of food security. Bioimaging will also bring the image-enabled database to manage MRI images, mammograms and electronic documents, and to facilitate regulatory submission and review of data gathered in the program.
Bracco Imaging S.P.A, Bayer HealthCare, Esaote S.p.A, Digirad Corporation are some of the key players in Bio-imaging market”
Key industry players are Bayer HealthCare, Bracco Imaging, S.P.A, Digirad Corporation, Covidien Pharmaceuticals, Esaote S.p.A, FONAR Corporation, GE Healthcare, Hologic Inc, Lantheus Medical Imaging, Inc., Hitachi Medical Corporation, Mindray Medical International Limited.
